Cytosorbents (CTSO) Competitors

Cytosorbents has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, CVRx has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Cytosorbents has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 7.3% of Cytosorbents shares are owned by company insiders. Comparatively, 13.9% of CVRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cytosorbents has a net margin of -31.85% compared to CVRx's net margin of -89.14%. CVRx's return on equity of -120.76% beat Cytosorbents' return on equity.

In the previous week, Cytosorbents had 12 more articles in the media than CVRx. MarketBeat recorded 17 mentions for Cytosorbents and 5 mentions for CVRx. CVRx's average media sentiment score of 0.54 beat Cytosorbents' score of 0.34 indicating that CVRx is being referred to more favorably in the news media.

Cytosorbents presently has a consensus target price of $5.38, suggesting a potential upside of 1,026.83%. CVRx has a consensus target price of $11.50, suggesting a potential upside of 96.08%. Given Cytosorbents' higher possible upside, research analysts clearly believe Cytosorbents is more favorable than CVRx.

Cytosorbents has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

Cytosorbents has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

In the previous week, Cytosorbents had 7 more articles in the media than Microbot Medical. MarketBeat recorded 17 mentions for Cytosorbents and 10 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.74 beat Cytosorbents' score of 0.34 indicating that Microbot Medical is being referred to more favorably in the news media.

Microbot Medical has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Microbot Medical's return on equity of -21.84% beat Cytosorbents' return on equity.

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 7.3% of Cytosorbents shares are owned by company insiders. Comparatively, 4.7% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cytosorbents presently has a consensus target price of $5.38, indicating a potential upside of 1,026.83%. Microbot Medical has a consensus target price of $7.50, indicating a potential upside of 350.45%. Given Cytosorbents' higher possible upside, equities analysts plainly believe Cytosorbents is more favorable than Microbot Medical.

Cytosorbents has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Sanuwave Health has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

Sanuwave Health has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are held by institutional investors. 7.3% of Cytosorbents shares are held by company insiders. Comparatively, 14.4% of Sanuwave Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Cytosorbents had 8 more articles in the media than Sanuwave Health. MarketBeat recorded 17 mentions for Cytosorbents and 9 mentions for Sanuwave Health. Cytosorbents' average media sentiment score of 0.34 beat Sanuwave Health's score of -0.17 indicating that Cytosorbents is being referred to more favorably in the media.

Sanuwave Health has a net margin of 35.96% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat Sanuwave Health's return on equity.

Cytosorbents currently has a consensus price target of $5.38, suggesting a potential upside of 1,026.83%. Sanuwave Health has a consensus price target of $51.00, suggesting a potential upside of 197.03%. Given Cytosorbents' higher possible upside, equities research analysts plainly believe Cytosorbents is more favorable than Sanuwave Health.

Cytosorbents has a net margin of -31.85% compared to Avita Medical's net margin of -62.67%. Avita Medical's return on equity of 0.00% beat Cytosorbents' return on equity.

Avita Medical has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Cytosorbents has lower revenue, but higher earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Avita Medical presently has a consensus price target of $7.25, suggesting a potential upside of 69.51%. Cytosorbents has a consensus price target of $5.38, suggesting a potential upside of 1,026.83%. Given Cytosorbents' higher probable upside, analysts plainly believe Cytosorbents is more favorable than Avita Medical.

27.7% of Avita Medical shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 2.8% of Avita Medical shares are owned by company insiders. Comparatively, 7.3% of Cytosorbents shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Cytosorbents had 6 more articles in the media than Avita Medical. MarketBeat recorded 17 mentions for Cytosorbents and 11 mentions for Avita Medical. Cytosorbents' average media sentiment score of 0.34 beat Avita Medical's score of 0.32 indicating that Cytosorbents is being referred to more favorably in the news media.